RxDoctor Payments Data

Saleem Akbar, MD

Cardiovascular Disease · Allen, TXNPI 1417925298

Payments from drug & device makers

$297,941in general payments, 2019–2025

Across 473 payments — averaging $629.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$103K
  • Esperion Therapeutics, Inc.$75K
  • Boehringer Ingelheim Pharma GmbH & Co.kg$33K
  • Boehringer Ingelheim International GmbH$32K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$23K
  • Novartis$22K
  • plus $11K from 35 others

What the payments were for

  • Food & beverage$5,84898%
  • Education$932%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$297,941 in reported general payments places this provider in the 90th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$214,487
Medicare patients
568
Services billed
2,370

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban185$170,720
XareltoRivaroxaban77$69,125
EntrestoSacubitril/Valsartan65$66,645
FarxigaDapagliflozin Propanediol49$43,012
OzempicSemaglutide20$38,212
JardianceEmpagliflozin25$26,573
EdarbyclorAzilsartan Med/Chlorthalidone29$14,084
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$12,254
Janumet XrSitagliptin Phos/Metformin Hcl15$11,990
LivaloPitavastatin Calcium11$10,325
Praluent PenAlirocumab16$9,957
EdarbiAzilsartan Medoxomil17$9,432
Repatha SureclickEvolocumab12$6,913
Nifedipine ErNifedipine209$5,322
Metoprolol Succinate354$4,922

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$106$170,720185 claims
Johnson & JohnsonXarelto$437$69,12577 claims
NovartisEntresto$21,631$66,64565 claims
AstraZenecaFarxiga, Breztri Aerosphere$103,064$55,26662 claims
Novo NordiskOzempic$99$38,21220 claims
Boehringer IngelheimJardiance$166$26,57325 claims
Arbor Pharmaceuticals, Inc.Edarbyclor, Edarbi$209$23,51646 claims
MerckJanumet Xr$585$11,99015 claims
Kowa Pharmaceuticals America, Inc.Livalo$811$10,32511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Allen

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →